How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,667 results for

Medication Causes of Dyspnea

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

2. Comparison of health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis protocol. Full Text available with Trip Pro

Comparison of health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis protocol. Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and causes patients considerable burden; symptoms such as palpitations and dyspnoea are common, leading to frequent emergency room visits. Patients with AF report reduced health-related quality of life (HQOL) compared with the general (...) population; thus, treatments focus on the restoration of sinus rhythm to improve symptoms. Catheter ablation (CA) is a primary treatment strategy to treat AF-related burden in select patient populations; however, repeat procedures are often needed, there is a risk of major complications and the procedure is quite costly in comparison to medical therapy. As the outcomes after CA are mixed, an updated review that synthesises the available literature, on outcomes that matter to patients, is needed so

2017 BMJ open

3. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai October 2019 EUnetHTA Joint Action 3 WP4 1 EUnetHTA Joint Action 3 WP4 Version 1.0, 22/10/2019 Relative effectiveness assessment of pharmaceutical technologies USTEKINUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE (...) and Pharmaceutical Benefits Agency (TLV). Relative effectiveness assessment of pharmaceutical technologies. Ustekinumab for the treat- ment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. EUnetHTA Project ID: PTJA07. 2019. PTJA07 - Ustekinumab for active ulcerative colitis October 2019 EUnetHTA Joint Action 3

2020 EUnetHTA

4. Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs

synthetic opioids as reported in the media and in other sources of information in Canada and the United States. Finally, the bulletin includes a discussion of the implications of this phenomenon for those working in: ? Public health and harm reduction ? Emergency medical services and emergency response services ? Laboratories ? Poison control centres ? Law enforcement Reports of Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs The following table provides a non (...) involving this drug.” 15 On May 20, the Office of the Chief Medical Examiner of Alberta issued a statement that W-18 was detected in a man who had died. However, because of the presence of other drugs, the Office could not confirm that W-18 was the cause of death. 16 On June 1, 2016, the Government of Canada announced that it had, on the recommendations of Health Canada, published final amendments adding W-18 to Schedule 1 of the Controlled Drugs and Substances Act and Part I of the Schedule to Part J

2016 Canadian Centre on Substance Abuse

5. Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults

Disease Gynaecology Womens Sexual Health and Benign Breast Disease Haematology and Blood Products Health Promotion and Protection including Screening Immunology and Allergy Infectious Disease and Immunisation Mens Health and Sexual Health Mental Health Drug Abuse and Learning Difficulties Musculoskeletal Neurology and Neurosurgery Other Paediatrics and Neonatology Pregnancy and Childbirth Radiology Imaging and Nuclear Medicine Rehabilitation and Disability Renal Disease and Urology Respiratory Disease (...) is a neurological condition that affects nerve cells in the brain and spinal cord. It results in gradual weakness and wasting of muscles of the body. Respiratory muscles are involved as the disease progresses, leading to shortness of breath and ultimately death. Little is known about the cause of the disease, and there is currently no cure. August 2018 Inebilizumab is a humanised monoclonal antibody that is in clinical development for reducing the risk of an attack in patients with Neuromyelitis Optica Spectrum

2017 NIHR Innovation Observatory

6. Acute Coronary Syndromes: Initial Medical Therapy

. Anti-platelet therapy for Acute Coronary Syndrome: A review of currently available agents and what the future holds. Cardiovasc Hematol Disord Drug Targets 2011;11:79-86. 20. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England journal of medicine 2001;345:494-502. 21. Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients (...) Acute Coronary Syndromes: Initial Medical Therapy ANZCOR Guideline 14.2 January 2016 Page 1 of 10 ANZCOR Guideline 14.2 – Acute Coronary Syndromes: Initial Medical Therapy Guideline Who does this guideline apply to? This guideline applies to adult victims. Who is the audience for this guideline? This guideline is for use by health professionals. 1 Symptomatic Therapy There are a number of therapies in patients with Acute Coronary Syndromes (ACS) that provide relief for symptoms. Supplemental

2016 Australian Resuscitation Council

7. Medication Causes of Dyspnea

Medication Causes of Dyspnea Aka: Medication Causes of Dyspnea , Dyspnea due to Drugs From Related Chapters II. Causes Medications that provoke s s or Pneumonitis or causes Bleomycin Chlorambucil Cyclophosphamide Melphalan Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Medication Causes of Dyspnea." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related (...) Medication Causes of Dyspnea Medication Causes of Dyspnea Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Medication Causes of Dyspnea

2018 FP Notebook

8. Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Full Text available with Trip Pro

, and the duration of the other study was 15 days.We were unable to conduct many of our predetermined analyses due to different agents, dosages, comparators and outcome measures, routes of drug delivery, measurement scales and time points. Subgroup analysis according to type of cancer was not possible.Primary outcomesWe included two studies (114 participants) with data at one week in the meta-analysis for change in dyspnoea intensity/dyspnoea relief from baseline. Corticosteroid therapy with dexamethasone (...) Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Dyspnoea is a common symptom in advanced cancer, with a prevalence of up to 70% among patients at end of life. The cause of dyspnoea is often multifactorial, and may cause considerable psychological distress and suffering. Dyspnoea is often undertreated and good symptom control is less frequently achieved in people with dyspnoea than in people with other symptoms of advanced cancer, such as pain

2019 Cochrane

9. Intrapartum care for women with existing medical conditions or obstetric complications and their babies

a cardiac-specific history and suspect heart failure if there is not another likely cause of any of the following symptoms: Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated April 2019 Page 14 of 96breathlessness when lying down (ruling out aortocaval compression) or at rest unexplained cough (...) medical conditions or obstetric complications and their babies (NG121) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated April 2019 Page 24 of 961.6.11 Be aware that non-steroidal anti-inflammatory drugs can add to the risk of bleeding. 1.6.12 Before discharge from hospital, inform women with bleeding disorders of the risk of secondary bleeding postpartum and how to access care. T o find out why the committee

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

10. Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma Full Text available with Trip Pro

Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma Cystic fibrosis (CF) is a disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator protein in the epithelial membrane, and affects at least 30,000 people in the USA. There are between 900 and 1000 new cases diagnosed every year. Traditionally, CF has been treated symptomatically with pancreatic enzymes, bronchodilators, hypertonic saline, and pulmozyme. In July 2015, the US Food (...) and Drug Administration approved Orkambi (lumacaftor/ivacaftor), a combination drug that works on reversing the effects of the defective cystic fibrosis transmembrane conductance regulator protein. Orkambi and mucolytics decrease the viscosity of mucous secretions, leading to an accumulation of hypoviscous fluid in the alveoli, resulting in dyspnea. This presentation can be mistaken for an infective exacerbation. We present a case in which a young female with CF recently started on Orkambi therapy

2017 International medical case reports journal

11. Drugs That May Cause or Exacerbate Heart Failure Full Text available with Trip Pro

to 23 different providers annually in both the inpatient and outpatient settings, which could in turn increase the number of prescription medications prescribed. As the number of prescription medications increases, so does the potential for adverse drug events and drug-drug interactions. Goldberg et al found that patients taking at least 2 prescription medications had a 13% risk of an adverse drug-drug interaction, which increased to 38% for 4 medications and 82% with ≥7 medications. Drugs may cause (...) or exacerbate HF by causing direct myocardial toxicity; by negative inotropic, lusitropic, or chronotropic effects; by exacerbating hypertension; by delivering a high sodium load; or by drug-drug interactions that limit the beneficial effects of HF medications. To avoid these negative effects, healthcare providers need a comprehensive and accessible guide of the prescription medications, OTC medications, and CAMs that could exacerbate HF. Using case reports, case series, package inserts, meta-analyses

2016 American Heart Association

12. Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines

of > grade 3 pneumonitis (HR 0.33) compared to 3D conformal radiotherapy. The volume of lung receiving 20 Gy (V20) was significantly lower in the 4DCT/IMRT group. The American Association of Physicists in Medicine (AAPM) Task Group 76 guidelines summarized the adequate methods to account for this respiratory motion including 4DCT, slow CT, inhale/ exhale/breath-hold CT, respiratory gating with internal fiducial markers or external markers to signal respiration, breath hold, abdominal compression (...) for medical necessity review , due to billing practices or claims that are not consistent with other providers in terms of frequency or some other manner. CPT ® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT ® five digit codes, nomenclature and other data are copyright by the American Medical Association. All Rights Reserved. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data

2018 AIM Specialty Health

13. Management of Cancer Medication-Related Infusion Reactions

Advisors who reviewed the patient information sheet Expert Reviewers Dr. Peter Vadas, Head, Division of Allergy and Clinical Immunology, St. Michael’s Hospital Dr. Baruch Jakubovic, Division of Clinical Immunology, Department of Medicine, University of Toronto Dr. Silvana Spadafora, Medical Oncologist/Chief of Staff, Algoma District Cancer Program, Sault Area Hospital Dana Root, Lead Oncology Pharmacist, Windsor Regional Hospital Diana Incekol, Advanced Practice Nurse Educator, Princess Margaret Cancer (...) with a drug’s mechanism of action. 1,2 The incidence of IRs varies depending on the anticancer agent used. In some cases, the incidence of reactions may be low but the risk for potentially life-threatening reactions exists. 2,3 Most IRs occur within the first hour of either the first or second administration of an intravenous anticancer medication; therefore, careful monitoring during infusion initiation is necessary to detect potential IRs and manage accordingly. 3 In cases where IRs may be prevented

2019 Cancer Care Ontario

14. Guidelines on Management of Dyspnea (Breathlessness) in Patients with Cancer

include relaxation, breathing exercises, cool air flow with a hand-held fan, and use of a walker or other aids to support mobility. The Alberta Health Services guideline [13] covers superior vena cava obstruction (SVCO, from cancer) and malignant airway obstruction, both of which may result in dyspnea. Approximately 85% to 90% of SVCO is caused by cancer, mostly from lung cancer and a smaller proportion from lymphomas and leukemias. Sudden-onset SVCO should be considered a medical emergency [59 (...) this literature review. RESULTS AND DISCUSSION Dyspnea Definition and Background The American Thoracic Society [8,9] defines dyspnea as “a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social, and environmental factors, and may induce secondary physiological and behavioral responses.” Other terminology for dyspnea includes breathlessness, difficult

2019 Cancer Care Ontario

15. Inter-arytænoid and Subglottic Infiltration of Fifteen Months' Duration, causing Difficulty of Breathing which necessitated Tracheotomy Full Text available with Trip Pro

Inter-arytænoid and Subglottic Infiltration of Fifteen Months' Duration, causing Difficulty of Breathing which necessitated Tracheotomy 19973595 2010 06 22 2010 06 22 0035-9157 2 Laryngol Sect 1909 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Inter-arytaenoid and Subglottic Infiltration of Fifteen Months' Duration, causing Difficulty of Breathing which necessitated Tracheotomy. 10-1 Tilley H H eng Journal Article England Proc R Soc Med 7505890 0035-9157 2009 12 9 6 0 1909 1

1909 Proceedings of the Royal Society of Medicine

16. Intraluminal tracheal lipoma as a rare cause of dyspnoea in a dog Full Text available with Trip Pro

Intraluminal tracheal lipoma as a rare cause of dyspnoea in a dog Tracheal tumors are rarely diagnosed in veterinary medicine and the majority of tracheal neoplasia reported in adult dogs are malignant. Intratracheal lipoma has not been previously reported in the veterinary literature.A 7-year-old Briard dog was evaluated for inspiratory dyspnoea and an inspiratory wheeze. Cervical radiographs and tracheoscopic examination revealed an intratracheal mass that was surgically removed. The dog has

2018 Acta veterinaria Scandinavica

17. Closed-system transfer-devices for limiting exposure to cytotoxic anti-cancer drugs in healthcare professionals, patients and visitors

, the clinical importance of this reduction is unknown. ? Four studies reporting a range of guidelines for the safe-handling of hazardous drugs recommended implementation of training, personal protective equipment (PPE), CSTDs, medical surveillance and other safety measures, largely based on expert consensus. SHTG Evidence Synthesis | 3 Contents Definitions 4 Literature search 4 Introduction 4 Description of health problem 6 Health technology description 6 Clinical effectiveness 7 Cost effectiveness 14 (...) Organisational issues/context 15 Identified research gaps 16 Conclusion 16 Equality and diversity 17 Acknowledgements 17 References 18 SHTG Evidence Synthesis | 4 Definitions Antineoplastic: Blocking the formation of neoplasms (growths that may become cancer) 1 . Cytotoxic drug: A substance that kills cells, including cancer cells. These agents may stop cancer cells from dividing and growing and may cause tumors to shrink in size 1 . Carcinogen: Any substance that causes cancer 1 . Genotoxic: Denoting

2019 SHTG Advice Statements

18. The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies

The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review) | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share October 13, 2009 ; 73 (15) Special Article Practice (...) Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology R. G. Miller , C. E. Jackson , E. J. Kasarskis , J. D. England , D. Forshew , W. Johnston , S. Kalra , J. S. Katz , H. Mitsumoto , J. Rosenfeld , C. Shoesmith , M. J. Strong , S. C. Woolley First published October 12, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181bc0141 R

2009 American Academy of Neurology

19. Palliative drug treatments for breathlessness in cystic fibrosis. Full Text available with Trip Pro

Palliative drug treatments for breathlessness in cystic fibrosis. Cystic fibrosis is a life-limiting autosomal recessive genetic illness. A feeling of shortness of breath is common in cystic fibrosis, especially as the disease progresses. Reversing the underlying cause is the priority when treating breathlessness (dyspnoea), but when it is not feasible, palliation (easing) becomes the primary goal to improve an individual's quality of life. A range of drugs administered by various routes have (...) . The research should focus on the efficacy and safety of the drugs with efficacy being measured in terms of improvement in quality of life, dyspnoea scores and hospital stay.

2017 Cochrane

20. A case of drug induced lung injury caused by levofloxacin eye drops Full Text available with Trip Pro

A case of drug induced lung injury caused by levofloxacin eye drops A 78 year-old man, who received levofloxacin eye drops as a perioperative prophylactic antibacterial agent for cataract surgery, developed pyrexia and dyspnea, followed by respiratory failure. He was diagnosed as drug-induced lung injury due to levofloxacin, and the symptoms improved after the administration of corticosteroids and discontinuation of levofloxacin eye drops. The incidence of levofloxacin-induced lung injury (...) is rare for its frequent prescription. Moreover, eye drops of it has never been reported to cause lung injury. We should be aware of eye drops as a causative dosage forms of drug-induced lung injury.

2018 Respiratory Medicine Case Reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>